Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Sells $69,050.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 1,250 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $55.24, for a total transaction of $69,050.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at $662,880. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Eric Aguiar also recently made the following trade(s):

  • On Wednesday, November 20th, Eric Aguiar sold 6,729 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $52.20, for a total transaction of $351,253.80.
  • On Wednesday, September 11th, Eric Aguiar sold 10,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00.

Shares of NYSE:BHVN traded up $2.62 on Friday, reaching $56.50. 1,293,400 shares of the company were exchanged, compared to its average volume of 710,037. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $29.17 and a 1-year high of $67.86. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of -9.19 and a beta of 0.34. The company has a 50-day moving average of $46.50 and a 200-day moving average of $47.40.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47). As a group, analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -7.57 earnings per share for the current year.

Several brokerages have issued reports on BHVN. Goldman Sachs Group set a $89.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. Wedbush started coverage on shares of Biohaven Pharmaceutical in a research note on Thursday. They set an “outperform” rating and a $75.00 price target on the stock. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, August 26th. Finally, ValuEngine cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $72.09.

Large investors have recently bought and sold shares of the company. GW&K Investment Management LLC grew its stake in Biohaven Pharmaceutical by 41.5% in the 3rd quarter. GW&K Investment Management LLC now owns 146,376 shares of the company’s stock valued at $6,107,000 after acquiring an additional 42,896 shares during the last quarter. Eagle Asset Management Inc. grew its stake in Biohaven Pharmaceutical by 0.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 984,335 shares of the company’s stock valued at $41,066,000 after acquiring an additional 2,939 shares during the last quarter. First Mercantile Trust Co. acquired a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at about $148,000. Trellus Management Company LLC grew its stake in Biohaven Pharmaceutical by 21.5% in the 3rd quarter. Trellus Management Company LLC now owns 7,900 shares of the company’s stock valued at $330,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at about $801,000. 90.39% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

See Also: What is the G-20?

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.